Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Lake Street raises Silk Road Medical stock PT, citing strong Q4 and 2024 outlook

Published 2024-04-29, 09:46 a/m

On Monday, Lake Street Capital Markets adjusted their financial outlook for Silk Road Medical (NASDAQ: NASDAQ:SILK), boosting the price target to $28 from the previous $20, while maintaining a Buy rating on the company's stock. The adjustment follows a reported quarter that surpassed expectations and a positive view of the year ahead.

Q4 revenue and the guidance for 2024 have both exceeded initial projections, signaling a recovery from last year's challenges, which included reimbursement changes, commercial disruptions, and a CEO transition. The appointment of the new CEO approximately three months ago has been seen as a turning point for the company. The analyst noted that the Q4 results might indicate that the market's concerns were overstated.

Despite potential competition from transfemoral carotid artery stenting (TF-CAS), the analyst believes that Silk Road Medical's TransCarotid Artery Revascularization (TCAR) procedure will not be significantly impacted and will continue to be adopted as a standard of care. The Q4 strength was attributed to regular procedural demand during the year's seasonally strongest quarter, with growth driven by demand rather than inventory stocking.

The company's forward guidance suggests a 10%-12% increase in top-line growth. With CEO McKhann still relatively new in the role, the forecast is considered to have a conservative slant.

Silk Road Medical also addressed last year's commercial disruptions, stating that a third of the commercial team has been onboard for less than a year. The company assured that the foundation for growth is solid and that the new representatives are expected to progress normally.

The analyst expressed confidence in the company's commercial strategy, which focuses on encouraging physicians to adopt a "TCAR first" approach.

Despite a reduction in the valuation gap, Lake Street Capital Markets believes that there is still room for the stock's value to rise, especially when compared to competitors' valuations, which are around 6x 2024 EV/Revenue, while Silk Road Medical is currently trading at 3x. The firm reiterates its Buy rating and has increased its price target to $28 in light of these considerations.

InvestingPro Insights

Following the upbeat assessment by Lake Street Capital Markets, it's worth considering the latest financial data and analyst trends for Silk Road Medical (NASDAQ: SILK) as provided by InvestingPro. The company's market capitalization stands at a robust $702.07M, reflecting investor confidence despite the absence of profitability in the last twelve months. The company's revenue has shown a healthy growth of 27.77% over the last year, indicating a strong demand for its medical procedures and potential for future expansion.

InvestingPro Tips suggest an optimistic outlook from analysts, with four of them revising their earnings upwards for the upcoming period. This could be indicative of Silk Road Medical's potential to exceed performance expectations in the near future. Additionally, the company's strategic financial positioning is evident as it holds more cash than debt, a reassuring sign for investors concerned about the company's solvency. Liquid assets also surpass short-term obligations, further underscoring the company's financial stability.

While the company does not pay a dividend, which might deter income-focused investors, the substantial price uptick of 164.49% over the past six months could be appealing for growth-oriented shareholders. For those looking to delve deeper into Silk Road Medical's financials and future prospects, additional InvestingPro Tips are available. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to a wealth of information that could inform your investment decisions. There are currently 6 more tips available on InvestingPro for Silk Road Medical that could provide further insights into the company's potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.